Finally, a variety of novel high-throughput immunological screening methods, with enhanced capacity to interrogate large numbers of candidate neoepitopes, are used to screen cancer-derived CD8+ and CD4+ T-cell populations of interest for neoantigen recognition. This evidence concerns the gene CD8A and cancer.